inHEART

High-Level Overview

inHEART is a deep-tech healthcare startup founded in 2017 and headquartered in Pessac, France, with a US subsidiary in Boston. The company builds AI-driven, web-based SaaS solutions that create highly detailed 3D digital twins of the heart from CT and MR images, electrocardiograms, and other data, primarily serving cardiologists and electrophysiologists to support cardiac arrhythmia treatment, pre-procedural planning for ablations, and screening for diseases like sudden cardiac death, heart failure, and cardio-embolic stroke.[1][2][3] These models solve key challenges in conventional cardiac ablations by providing unprecedented anatomical details of tissue and scar structures, enabling faster procedures, optimized strategies, and improved outcomes while integrating seamlessly with major electroanatomic mapping systems.[2][3] inHEART has secured Class II CE mark, 510(k) clearance, and $11 million in funding as of recent rounds to fuel commercial growth, with strong clinical evidence and participation in initiatives like the French MEDITWIN consortium.[1][2]

Origin Story

inHEART emerged from the MUSIC (Multi-modality Platform for Specific Imaging in Cardiology) research project, which laid the groundwork for its core technology. CTO Nicolas Pegatoquet, who joined in 2017 as a developer after leading the MUSIC effort, advanced from managing the development team to his current role; he later earned a University Diploma in Cardiac Electrophysiology from the University of Montpellier in 2020 to deepen his cardiac expertise.[4] Chairman and CEO Todor Jeliaskov leads the company, emphasizing prevention over reaction in cardiac care, as highlighted in collaborations like MEDITWIN targeting sudden cardiac death.[1][2] Early traction included gathering substantial clinical evidence for regulatory approvals and partnerships with EIT Health to enhance AI and evidence, setting the stage for $11M funding to scale from screening to advanced therapies.[2]

Core Differentiators

• Proprietary AI Segmentation: Uses advanced algorithms to analyze CT/MR images and ECG data, generating interactive 3D models with precise tissue, scar, and structural details unavailable in standard imaging—critical for targeting arrhythmogenic areas in complex cases like ventricular tachycardia (VT).[1][2][3]
• Pre-Procedural Optimization: Enables physicians to plan ablations outside the lab, reducing procedure time, simplifying strategies, and improving precision/safety; clinicians report it as "invaluable" and "beyond expectations" for challenging VT and cardioneuroablation cases.[3]
• Seamless Workflow Integration: Web-based SaaS compatible with all major electroanatomic mapping (EAM) systems, allowing easy import and collaboration across hospitals without disrupting clinical routines.[3]
• Preventive and Predictive Focus: Extends beyond treatment to early screening for sudden cardiac death (800,000+ annual cases), heart failure, and strokes, shifting healthcare from reactive to proactive via digital twins.[1][2]
• Regulatory and Clinical Validation: Class II CE mark, 510(k) clearance, and involvement in studies like inEurHEART, backed by EIT Health and consortia like MEDITWIN.[1][2]

Role in the Broader Tech Landscape

inHEART rides the wave of AI-powered digital twins in healthcare, applying industrial virtual twin tech—pioneered by firms like Dassault Systèmes—to cardiology for personalized medicine.[1] Timing aligns with surging demand for precision interventions amid rising cardiac diseases, where traditional ablations face high recurrence and complexity; AI segmentation addresses this by unlocking "invisible" heart mechanics.[1][3] Market forces like regulatory nods (CE/510(k)), EIT Health support, and $11M funding favor scaling, while clinician adoption (e.g., Hartford Healthcare, UPenn) validates impact.[2][3] The company influences the ecosystem by advancing image-guided therapies, collaborating on national initiatives like MEDITWIN, and enabling faster, safer care—potentially reducing global sudden cardiac death burdens through preventive screening.[1][2]

Quick Take & Future Outlook

inHEART is poised for global expansion with recent leadership additions like Randy Jordan as Chairman (July 2025), bolstering its push into US markets and AI refinements.[3] Upcoming milestones include inEurHEART study results, deeper MEDITWIN integration, and commercial rollout of predictive tools for broader cardiac risks.[1][3] Trends like AI-healthcare convergence, regulatory tailwinds for digital twins, and emphasis on preventive cardiology will propel growth, evolving inHEART from ablation optimizer to comprehensive cardiac platform—ultimately transforming reactive care into predictive prevention, much like its MUSIC origins revolutionized imaging.[2][4]